GLP-1

• Semaglutide (Ozempic, Rybelsus, Wegovy)
• Dulaglutide (Trulicity)
• Exenatide extended release (Bydureon BCise)
• Exenatide (Byetta)
• Liraglutide (Victoza, Saxenda)
• Lixisenatide (Adlyxin)

• Age: 18+
• Gender: All genders
• Diagnosis: ICD codes: 
  • E11.9**: Type 2 diabetes mellitus without complications
  • E11.65**: Type 2 diabetes mellitus with hyperglycemia
    
  • E11.22**: Type 2 diabetes mellitus with diabetic chronic kidney disease
    
  • E11.29**: Type 2 diabetes mellitus with other diabetic kidney complications
  • E66.01**: Morbid obesity due to excess calories
  • E66.9**: Obesity, unspecified
  • Z68.41**: Body mass index (BMI) 40.0-44.9, adult
  • Z68.42**: Body mass index (BMI) 45.0-49.9, adult
• Treatment: Prescribed a GLP-1 receptor agonist 
• Observation Period: 12 months prior to initiation of GLP-1 treatment through 1/1/2025

“All ResearchNexo Data Collection must follow the ResearchNexo Data Collections Specifications“

Anonymized data set containing in CSV, excel or SQL formats.

Data fields per item required:

• Patient Table: Includes all patients satisfying the cohort requirements.
• Condition Table: Includes all diagnoses associated with cohort members during the observation period
• Procedure Table: Includes all procedures associated with cohort members during the observation period
• Treatment Table: Includes all medications (semaglutide and all other drugs) associated with cohort members during the observation period
• Measurement Table: Includes all laboratory tests associated with cohort members during the observation period